Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

被引：211

作者：

Martin, AM ^{[1
]}

Nolan, D

James, I

Cameron, P

Keller, J

Moore, C

Phillips, E

Christiansen, FT

Mallal, S

机构：

[1] Royal Perth Hosp, Ctr Clin Immunol & Biomed Stat, Perth, WA, Australia

[2] Murdoch Univ, Perth, WA, Australia

[3] Royal Perth Hosp, Dept Clin Immunol & Biochem Genet, Perth, WA, Australia

[4] Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Clin Pharmacol, Toronto, ON, Canada

[5] Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Infect Dis, Toronto, ON, Canada

[6] Univ Western Australia, Sch Surg & Pathol, Nedlands, WA 6009, Australia

来源：

AIDS | 2005年 / 19卷 / 01期

关键词：

D O I：

10.1097/00002030-200501030-00014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Genetic (human leukocyte antigen), disease-related and demographic risk factors for nevirapine reactions were examined in a nevirapine-exposed cohort. Cases involving combinations of hepatitis, fever or rash were associated with an interaction between HLA-DRB1*0101 and the percentage of CD4, whereas no associations were detected for isolated rash. These data suggest that HLA-DRB1*0101 and the CD4 status may determine susceptibility to nevirapine hypersensitivity, consistent with a CD4 T-cell-dependent immune response to nevirapine-specific antigens.

引用

页码：97 / 99

页数：3

共 5 条

[1] *BOEHR ING PHARM I, 2003, VIR PACK INS
[2] Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors
Dieterich, DT
Robinson, PA
Love, J
Stern, JO
[J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 : S80 - S89
[3] Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
Mallal, S
Nolan, D
Witt, C
Masel, G
Martin, AM
Moore, C
Sayer, D
Castley, A
Mamotte, C
Maxwell, D
James, I
Christiansen, FT
[J]. LANCET, 2002, 359 (9308) : 727 - 732
[4] Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals
Patel, SM
Johnson, S
Belknap, SM
Chan, J
Sha, BE
Bennett, C
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (02) : 120 - 125
[5] A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients
Stern, JO
Robinson, PA
Love, J
Lanes, S
Imperiale, MS
Mayers, DL
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 : S21 - S33

← 1 →